New ALS drug
(`Motor Neuron Disease` or `MND` also known as `Lou Gehrig's disease`)
You can edit text on your website by double clicking on a text box on your website. Alternatively, when you select a 
A previously unknown problem protein has been discovered
A specifically designed new ALS drug, RCH4, successfully suppresses it
 ​RCH4 is available free of charge on compassionate basis depending on availability and location

The time required to develop a new drug
and get Regulatory Authority approval

Of crucial importance to a person with ALS/MND is the fact that there will be no cure approved (even if one existed right now) until after the expected life span of some 90% of PALS. However, some who are taking one of the only two drugs which do have notable efficacy in extending life could have a realistic prospect of seeing major improvement in treatment.​​ EXAMPLES ​​
RCH4 may statistically increase life expectancy by four fold or more, although we do not make any claims, nor offer any interpretation of our clinical data which is provided by PALS themselves worldwide.
It must be said that this charity has many people who take this drug who maintain a relatively good lifestyle and continue to have a rewarding, fulfilled life. Please remember that the unwelcome news of a confirmed diagnosis is not necessarily all doom and gloom. Determination, a sense of humour and a positive mental attitude are very important to quality of life.
Refer to `Efficacy` links above
Note: "IND" = Investigational New Drug                       "NDA" = New Drug Application

Drugs that do slow the decline rate for ALS patients
(Sources: RC database >10,000 datum points p=0.0001. Radicava 6 momth trial report p=0.0013. Riluzole PRO-ACT database)

RCH4 statistically slows the decline rate by 70% (Data end 2017) when non-responders excluded from data, 63% when included.
(The above chart refers to genuine Radicava, NOT to counterfeit Rdaicava/Edaravone. The chart is limited to 6 months to match the 2016 Radicava clinical trial)